New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 28, 2014
07:15 EDTICPTIntercept shares should be bought amid biotech weakness, says Oppenheimer
After meeting with Intercept's management, Oppenheimer believes that the company's management successfully explained issues involving OCA lipids, and the firm is now more confident in the company's ability to deal with future regulatory uncertainties. Oppenheimer keeps an Outperform rating on the stock.
News For ICPT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 29, 2015
19:14 EDTICPTOn The Fly: After Hours Movers
Subscribe for More Information
16:31 EDTICPTIntercept gets breakthrough designation from FDA for steatohepatitis treatment
Intercept Pharmaceuticals announced that its investigational product obeticholic acid, or OCA, has received "breakthrough therapy designation" from the FDA for the treatment of patients with nonalcoholic steatohepatitis, or NASH, with liver fibrosis. This indication constitutes a population of patients with a serious and life-threatening condition reflected by a higher risk of progression to cirrhosis and liver failure. OCA is currently being developed for the treatment of several chronic liver diseases, including primary biliary cirrhosis, NASH and primary sclerosing cholangitis.
January 22, 2015
07:17 EDTICPTIntercept price target lowered to $300 from $500 at Deutsche Bank
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use